Neurodegenerative Disease

Category

The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials: Material Science or Marketing?

Is the world ready for GV-971(Oligomannate)? Because the first new approved Alzheimer’s drug in many years is coming to a clinical trial near you. Conditionally approved by China’s regulators, many in the West are skeptical. However, industry sponsor Green Valley...

UCSD Announces Alzheimer’s Disease Research Breakthrough: Obj-SCD Predicts Amyloid Accumulation & Neurodegeneration

University of California, San Diego School of Medicine, and Veterans Affairs San Diego Healthcare System researchers report discovering that the accumulation of amyloid, the abnormal protein linked to neurodegenerative conditions such as Alzheimer’s disease (AD),...

George Washington University Study Asks: Can Nilotinib be Repurposed from use for Specific Cancer to use for Parkinson’s Disease?

There is tremendous value in identifying new purposes for existing drugs. Recently, Georgetown University Medical Center (GUMC) embarked on a project to do just that for Parkinson’s disease with a cancer drug called nilotinib (Tasigna). They found that the drug in...

ADDF Invests $3m in Vaccinex Contingent for Alzheimer’s Disease Contingent on IRB Approval & Enrollment Milestones

The Alzheimer’s Drug Discovery Foundation (ADDF) has granted an award, in the form of an investment of up to approximately $3 million in Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and...

Researchers at Stanford Discover Common Denominator In Several Neurodegenerative Diseases

Investigators at the Stanford University School of Medicine have found, in both mouse brain models and human brain cultures, that Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, or Lou Gehrig’s disease, share a common mode of damaging...

Pin It on Pinterest